You are here: Industry Insights > Cannabinoids

News List

New CRO Focused on Cannabis-based Drug Trials Launched PharmaSources
May 23, 2024
Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.
Cannabinoids: The Next Frontier for Cosmeceuticals? cphi-online
June 21, 2021
The market for CBD is growing and it is not just the pharmaceutical industry that is exploring its potential.
Remove barriers restricting the research of controlled drugs, says RPS pharmatimes
May 17, 2021
The Royal Pharmaceutical Society (RPS) has called for changes to allow for the unrestricted, legitimate research of controlled drugs in response to a consultation from the Advisory Council on the Misuse of Drugs (ACMD).
CBD could be used to deliver drugs into the brain, research shows pharmafile
April 23, 2019
Cannabidiol (CBD), one of 113 cannabinoids in cannabis plants, could be used to deliver medicines into the brain, according to research published in the journal Molecular Pharmaceutics.
Senzer's inhaler delivers cannabinoids faster at lower doses biospectrumasia
September 29, 2018
Insys holds the license to use Senzer's device to deliver the cannabinoid, Dronabinol, in the US and the trial is part of its goal to achieve regulatory approval from the U.S. Food and Drug Administration.
Inhaler delivers cannabinoids faster at lower doses europeanpharmaceuticalreview
September 27, 2018
Researchers have released data on a clinical trial using specific inhalers and oral capsules to deliver cannabinoids to participants…
Can cannabinoids be used to treat cancer? worldpharmanews
November 07, 2017
When cannabinoids activate signaling pathways in cancer cells they can stimulate a cell death mechanism called apoptosis, unleashing a potent anti-tumor effect.
Cannabinoids suitable for migraine prevention europeanpharmaceuticalreview
June 30, 2017
A study has confirmed that cannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments.
GW planing to test its cannabinoids in cancer pharmatimes
February 10, 2017
GW Pharma is strengthening its focus on oncology after promising mid-stage data for its cannabis-based therapy in patients with a rare and aggressive brain tumour called glioblastoma multiforme (GBM).